Core Insights - Teva Pharmaceuticals presented new data from the ongoing IMPACT-TD Registry, showing that treatment with AUSTEDO and AUSTEDO XR significantly reduces the severity of involuntary movements in patients with tardive dyskinesia (TD) and improves their quality of life [1][2][6] Company Overview - Teva Pharmaceutical Industries Ltd. is a leading biopharmaceutical company with a focus on innovative medicines and a strong generics business, dedicated to improving patient health for over 120 years [21] Study Findings - The interim analysis of the IMPACT-TD Registry evaluated 27 adults with TD, revealing that 77% of participants reported improvements in their lives while on AUSTEDO or AUSTEDO XR [6][7] - Patient-reported improvements included 77% in speech/communication, 75% in eating, 65% in psychosocial impact, 59% in activities of daily living, and 50% in sleep/pain after three months of treatment [7] - The total motor score on the Abnormal Involuntary Movement Scale (AIMS) showed a mean decrease of -2.9, indicating a notable reduction in uncontrolled movements [7] Treatment Information - AUSTEDO and AUSTEDO XR are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. FDA for treating tardive dyskinesia and chorea associated with Huntington's disease [5][8] - The study included patients with common comorbid psychiatric disorders, such as bipolar disorder (41%), anxiety disorder (37%), depression (26%), and schizophrenia (19%), reflecting a diverse patient population [2]